Innovation

Innovation is part of the Stallergenes heritage. As early as 1992, the group began developing a major therapeutic solution, treatments via the sublingual route (solutions for application under the tongue), which now account for almost half of the world allergens market.

Since then the company has deployed its specific expertise in understanding and treating respiratory diseases and is pushing ahead with its commitment to Research & Development by carving out a unique position on the market for allergen immunotherapy.

This determination has grown over the past eight years with Stallergenes increasing R&D spending eightfold, and investment in this area equating about 20% of sales in 2010.

Stallergenes is now offering a new important innovation with the development of tablets.

The convergence of clinical evidence and the recognition of a European registration have established tablets as the future of allergen immunotherapy, as testified by the World Allergy Organization’s “position paper” of December 2009.

The guidelines of the European Medicines Agency, EMA, substantially inspired by the development of immunotherapy tablets, were published for the first time in July 2009. They definitively conferred the status of new therapeutic class on allergens.